ENTRY       D12607                      Drug
NAME        Respiratory syncytial virus vaccine;
            Respiratory syncytial virus vaccine, adjuvanted;
            Recombinant respiratory syncytial virus vaccine;
            Arexvy (TN);
            Abrysvo (TN)
PRODUCT     ABRYSVO (Pfizer Laboratories Div Pfizer)
            AREXVY (GlaxoSmithKline Biologicals SA)
REMARK      Therapeutic category: 6313
            Product: D12607<JP/US>
EFFICACY    Active immunization (RSV)
  DISEASE   Prevention of lower respiratory tract disease caused by respiratory syncytial virus [DS:H00401]
TARGET      RSV F protein [KO:K19261]
BRITE       USP drug classification [BR:br08302]
             Immunological Agents
              Vaccines
               Respiratory Syncytial Virus
                Respiratory Syncytial Virus Vaccine (Recombinant [Adjuvanted])
                 D12607  Respiratory syncytial virus vaccine
            Therapeutic category of drugs in Japan [BR:br08301]
             6  Agents against pathologic organisms and parasites
              63  Biological preparations
               631  Vaccines
                6313  Viral vaccines
                 D12607  Respiratory syncytial virus vaccine
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D12607
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D12607
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D12607
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D12607
///
